Skip to main content Back to Top
Advertisement

7/23/2019

Dicyclomine Oral Presentations

Products Affected - Description

    • Dicyclomine hydrochloride capsule, Teva, 10 mg, bottle, 1000 count, NDC 00591-0794-10

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • Lannett did not provide a reason for the shortage.
    • Mylan refuses to provide availability information.
    • Par Pharmaceuticals has dicyclomine oral solution available.
    • Teva did not provide a reason for the shortage.

Available Products

    • Dicyclomine hydrochloride capsule, Hikma, 10 mg, bottle, 100 count, NDC 00143-3126-01
    • Dicyclomine hydrochloride capsule, Hikma, 10 mg, bottle, 1000 count, NDC 00143-3126-10
    • Dicyclomine hydrochloride tablet, Hikma, 20 mg, bottle, 100 count, NDC 00143-1227-01
    • Dicyclomine hydrochloride tablet, Hikma, 20 mg, bottle, 1000 count, NDC 00143-1227-10
    • Dicyclomine hydrochloride capsule, Lannett, 10 mg, bottle, 100 count, NDC 00527-0586-01
    • Dicyclomine hydrochloride capsule, Lannett, 10 mg, bottle, 1000 count, NDC 00527-0586-10
    • Dicyclomine hydrochloride tablet, Lannett, 20 mg, bottle, 100 count, NDC 00527-1282-01
    • Dicyclomine hydrochloride tablet, Lannett, 20 mg, bottle, 1000 count, NDC 00527-1282-10
    • Dicyclomine hydrochloride solution, Par Pharmaceuticals, 10 mg/5 mL, 473 mL bottle, NDC 00603-1161-58
    • Dicyclomine hydrochloride capsule, Teva, 10 mg, bottle, 100 count, NDC 00591-0794-01
    • Dicyclomine hydrochloride tablet, Teva, 20 mg, bottle, 100 count, NDC 00591-0795-01
    • Dicyclomine hydrochloride tablet, Teva, 20 mg, bottle, 1000 count, NDC 00591-0795-10

Estimated Resupply Dates

    • Teva has 10 mg capsules in 1,000 count on back order and the company estimates a release date of early-August 2019.

Updated

Updated July 23, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 22, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins